Immunogenicity of cyclophosphamide-treated tumor cells
Affiliations
- PMID: 3250356
Item in Clipboard
Immunogenicity of cyclophosphamide-treated tumor cells
Arch Immunol Ther Exp (Warsz).
1988.
Abstract
The immunogenicity of cyclophosphamide-treated murine tumor cells was tested on syngeneic or semisyngeneic mice. The majority of mice immunized with modified Ehrlich carcinoma cells, L1210 leukemia cells or AA sarcoma cells survived after challenge with a lethal dose of unmodified tumor cells. Plasmacytomas RPC-5 and MOPC 104E were less immunogenic and L-1 sarcoma cells were not immunogenic.
Similar articles
-
Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.Cancer Treat Rep. 1985 Mar;69(3):285-91. Cancer Treat Rep. 1985. PMID: 3978657
-
Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.Cancer Res. 1985 Oct;45(10):4932-9. Cancer Res. 1985. PMID: 4027979
-
Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS).Prog Clin Biol Res. 1976;9:109-21. Prog Clin Biol Res. 1976. PMID: 1030796
-
Development of tumors as a result of graft-versus-host reaction.Exp Hematol. 1973;1(3):135-49. Exp Hematol. 1973. PMID: 4153858 Review. No abstract available.
-
In vivo-in vitro tumor systems: new models for studing the response of tumours to therapy.Lab Anim Sci. 1977 Oct;27(5 Pt 2):831-51. Lab Anim Sci. 1977. PMID: 338981 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical